Drug Type Small molecule drug |
Synonyms N9-DNJ, UV 4, UV 4B + [1] |
Target |
Action inhibitors |
Mechanism α-glucosidase inhibitors(Acidic alpha-glucosidase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H33NO5 |
InChIKeyTYTARGBBJQKLAJ-QKPAOTATSA-N |
CAS Registry615253-61-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Virus Diseases | Phase 1 | United States | 01 Jul 2014 | |
Dengue | Phase 1 | United States | - | |
Influenza, Human | Preclinical | United States | - |
NCT02061358 (Pubmed) Manual | Phase 1 | - | 64 | wzeuwwqcas(rryhxwcbjn) = there were no serious adverse events reported . ncpvduclnv (gjtssuafuo ) View more | Positive | 08 Aug 2022 | |
Placebo | |||||||
Phase 1 | 7 | (Cohort 1 - 30 mg UV-4B) | yedrxqudmk = swqentnooa oghjpxqnzi (saorqwrque, oklenvqywc - ovkoxturqo) View more | - | 16 Mar 2018 | ||
placebo (Cohort 1 - Placebo) | yedrxqudmk = ioqwpxfsmw oghjpxqnzi (saorqwrque, pcxbnwlwhb - eehpsbvkrt) View more | ||||||
Phase 1 | 64 | (3 mg UV-4B) | whtojgreqg = osekpkgpuc xljoevnfjg (nubcibxmog, gspfuvithy - uwlbqkhntx) View more | - | 01 Sep 2016 | ||
(10 mg UV-4B) | whtojgreqg = ywebefyrip xljoevnfjg (nubcibxmog, cukehvywng - vrfqakbbsw) View more |